



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/700,383	11/04/2003	Jean-Francois Savouret	RICL-110 (69769-011)	5818
35893 7590 01/05/2007 GREENBERG TRAURIG, LLP ONE INTERNATIONAL PLACE, 20th FL ATTN: PATENT ADMINISTRATOR BOSTON, MA 02110			EXAMINER KEYS, ROSALYND ANN	
			ART UNIT	PAPER NUMBER
			1621	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/05/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/700,383

Applicant(s)

SAVOURET ET AL.

Examiner

Rosalynd Keys

Art Unit

1621

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 November 2006 and 06 December 2006.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 9 and 11-32 is/are pending in the application.
- 4a) Of the above claim(s) 9 and 14-25 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 9, 11-13 and 26-32 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 9 and 11-32 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Art Unit: 1621

DETAILED ACTION

Status of Claims

1. Claims 9, and 11-32 are pending.
Claims 9, 11-13 and 26-32 are rejected.
Claims 9 and 14-25 are withdrawn from consideration.
Claims 1-8 and 10 are cancelled.

Continued Examination Under 37 CFR 1.114

2. A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on November 3, 2006 has been entered.

Election/Restrictions

3. Claims 9 and 14-25 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on May 2, 2005.
4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim Rejections - 35 USC § 112

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

Art Unit: 1621

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 28-30 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 28-30 are indefinite because of the presence of the group ~~Cl~~. ~~Cl~~ is not a recognizable substituent,

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8. Claims 11-13, 26-29 and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Suga (US 5,530,030).

Suga teaches a compound and composition comprising the compound having the claimed formula I, wherein R3 and R5 are Cl, R4 is H, R3' is OH or OMe, and R4' and R5' are H (see Table 1, in particular compound 7 and its methoxy form; and column 3, lines 46 to column 4, line 10). The Examiner believes that the amounts disclosed in Table 3 are within the claimed dosage range (based upon the average man's weight of 70 kg).

Claim Rejections - 35 USC § 103

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1621

10. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

11. Claims 11-13 and 26-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goodman (US 6,022,901) in view of Silverman (The Organic Chemistry of Drug Design and Drug Action, 1992, pp. 15-19).

Goodman teaches a pharmaceutical composition comprising resveratrol (3,5,4'-trihydroxy stilbene). See entire disclosure. The pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, creams, ointments, lotions or the like. The compounds may be administered orally, parenterally, transdermally, rectally, nasally, buccally, and topically (see column 6, line 19 to column 8, line 37). The amount of active compound will vary but is generally ranges from about 0.5 to 2.0 mg/kg (see column 8, lines 38-48).

The compound of Goodman differs from the instant compound by a known bioisosteric replacement (see Silverman, in particular page 19, wherein it is taught that OH, F, and Cl are classical isosteres). Silverman further teaches that bioisosteres are substituents or groups that have chemical and physical similarities, and which produce broadly similar biological properties (see page 19). It is taught that bioisosterism is a lead modification approach that has been shown to be useful to attenuate toxicity or to modify the activity of a lead.

One having ordinary skill in the art at the time the invention was made would have found it obvious to substitute the OH groups of resveratrol, as taught by Goodman, with either a Cl group or a F group, since Silverman teaches that these substituents are classical isosteres.

Response to Arguments

12. Applicant's arguments filed November 3, 2006 have been fully considered but they are not persuasive. The Applicant believes that Suga does not anticipate Claim 32 because Suga is directed to nematicides against pine wood nematodes containing chlorinated hydroxyl stilbenes. This argument is not persuasive because compound 7 is within the structural limitations of the compound as disclosed in

Art Unit: 1621


claim 32 and the compound 7 is disclosed in combination with carriers such as water and alcohol both of which are known pharmaceutical carriers.

Thus, the Examiner believes that claim 32 in addition to claims 11-13 and 26-29 are anticipated by Suga.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rosalynd Keys whose telephone number is 571-272-0639. The examiner can normally be reached on M, W & F 5:30-7:30 am & 1-5 pm; T & Th 5:30 am-4 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Rosalynd Keys
Primary Examiner
Art Unit 1621

December 22, 2006